

ALT Therapeutics
 268 Bardonia Road
 Bardonia, NY 10954

Dr. Dong Zhang
 Tel: 781-249-5392
 Email: dzhang12@nyit.edu



Industry: Biotech/Therapeutics

Management:

- Executive Leadership
CEO: TBD
CSO: Dong Zhang, PhD, Founder and associate Professor at the medical school of New York Institute of Technology
CFO: TBD
- Board
 Dong Zhang, PhD
 Others: TBA
- Scientific Advisory Board
 Dong Zhang, PhD
 Lee Zou, PhD, Co-founder and professor at Harvard Medical School
 Others: TBA

Legal:

- Corporate: TBD
- IP: TBD

Intellectual Property:

- FANCM-PCTUS2017/017863 (WO 2017/146947 A1)
- ATR-PCTUS2016/01279 (WO 2016/112374 A2)

Finance:

- Current Investors / Financing to Date: None
- Financing Sought
\$18 - \$25 million
 - Identifying and optimizing FANCM and ATR inhibitors
 - Performing pre-clinical testing on their efficacy and toxicity

Executive Summary: Founders of ALT Therapeutics identified two novel oncology drug targets, FANCM and ATR, two very important DNA damage response (DDR) proteins, for treating ALT cancers. Based on how cancers maintain their telomeres, they can be classified as either telomerase positive (TEL+) cancers, or alternative lengthening of telomere (ALT) cancers. 10% - 15% of all cancers are ALT cancers, which include some of the most deadly cancers, such as glioblastoma and pancreatic cancers. At present, most ALT cancers can only be treated with conventional chemotherapy and there is no effective targeted therapy for ALT cancers. ALT Therapeutics will develop potent small molecule inhibitors of FANCM (FANCMi), ATR (ATRI) and other DDR proteins with less toxicity to treat ALT cancers.

Company History: Founders of ALT Therapeutics, **Drs. Dong Zhang and Lee Zou**, identified and published in top scientific journals (PNAS-2017 and Science-2015) two novel therapeutic targets for ALT cancer treatment, FANCM and ATR. Many scientists throughout the world have further validated their findings. In 2019, Drs. Zhang and Zou cofounded ALT Therapeutics.

Market Opportunity / Unmet Need: At present, most ALT cancers can only be treated with conventional chemotherapy, which are often toxic and ineffective. For example, the 5-year survival rate for glioblastoma and pancreatic cancers, some of which are ALT cancers, remains in the lower single digits.¹ American Cancer Society estimates that there will be 27.4 million new cases of cancers each year by 2040.¹ Among them, **2.74 to 4.11 million** new cases will be ALT cancers. Market Research Future forecasts that by 2026, the worldwide market for ALT cancers is between **\$17.7 and \$26.5 billion**.²

Competition/competitive advantage: Currently, there is no effective targeted therapy available for ALT cancers. Targeted therapy is often more efficacious with low toxicity. The FANCMi and ATRI developed by ALT Therapeutics will be novel, efficacious and targeted therapeutic drugs with low toxicity. FANCMi will be the first-in-class oncology drug because currently there is no helicase inhibitors on the oncology drug market.

Products/Services:

ALT Therapeutics will develop ATRI and FANCMi, which will be launched as oncology drugs to treat ALT cancers by 2028 and 2030, respectively. In addition, we will identify other DDR targets and develop inhibitors to treat ALT and other types of cancers.

Commercial / Technical Milestones:

ALT therapeutics plans to file the Investigation New Drugs (INDs) for ATRI and FANCMi by 2023 and 2025, respectively, and market them by 2028 and 2030, respectively.

Financial model: By 2026, the forecasted worldwide market for ALT cancer drugs will be around \$20 billion. We thus estimate that total annual revenue for ATRI or FANCMi will likely reach more than \$1 billion within five year of their launch. Followings are the projections for each product:

	1 st yr	2 nd yr	3 rd yr	4 th yr	5 th yr
Revenue	0.2	0.3	0.4	0.6	1.0 (billion)
Gross profit	0.1	0.2	0.3	0.5	0.9 (billion)

Notes: 1: www.cancer.org/research/cancer-facts-statistics/global.html
 2: www.marketresearchfuture.com/